Daiwa Securities Group
ZNTL icon

Daiwa Securities Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Daiwa Securities Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-212
Closed -$1K – 1338
2024
Q3 		$1K Hold
212
– – ﹤0.01% 1267
2024
Q2 		$1K Hold
212
– – ﹤0.01% 1311
2024
Q1 		$3K Hold
212
– – ﹤0.01% 1253
2023
Q4 		$3K Hold
212
– – ﹤0.01% 1257
2023
Q3 		$4K Hold
212
– – ﹤0.01% 1184
2023
Q2 		$6K Hold
212
– – ﹤0.01% 1173
2023
Q1 		$4K Hold
212
– – ﹤0.01% 1169
2022
Q4 		$4K Hold
212
– – ﹤0.01% 1173
2022
Q3 		$5K Hold
212
– – ﹤0.01% 1166
2022
Q2 		$6K Buy
212
+80
+61% +$2.12K ﹤0.01% 1164
2022
Q1 		$6K Hold
132
– – ﹤0.01% 1167
2021
Q4 		$11K Sell
132
-22
-14% -$1.7K ﹤0.01% 1148
2021
Q3 		$10K Buy
154
+78
+103% +$4.5K ﹤0.01% 1143
2021
Q2 		$4K Hold
76
– – ﹤0.01% 1096
2021
Q1 		$3K Hold
76
– – ﹤0.01% 1123
2020
Q4 		$4K Buy
+76
New +$3.43K ﹤0.01% 1075

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Daiwa Securities Group's ZNTL Position: Q4 2024 in Review

Daiwa Securities Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2024, closing a stake of 212 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in ZNTL in Q4 2020 and held it in 16 quarters. The position peaked at $11K in Q4 2021. 142 funds tracked by Wall St. Rank hold ZNTL as of Q4 2024.

  • Daiwa Securities Group reported no remaining Zentalis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Daiwa Securities Group sold 212 Zentalis Pharmaceuticals shares in Q4 2024, an estimated $1K.
  • Daiwa Securities Group first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 16 quarters.
  • Daiwa Securities Group's Zentalis Pharmaceuticals position peaked at $11K in Q4 2021.
  • 142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2024.

Based on Daiwa Securities Group's 13F filing for Q4 2024, filed 7 Feb 2025.